tbuckley/cabot-search huggingface dataset:
Stent Revascularization for Renal Artery Stenosis in septuagenarians: does baseline creatinine influence 3 year survival?
Authors: G. Dorros, M.R. Jaff, S.R. Ramee, E.B. Diethrich, J.A. Rodiguez-Lopez, R.L. Minor, R.H. Harner, Z. Krajcer, K. Rosenfield, K.J. Murphy, T.Z. He
Journal: Journal of the American College of Cardiology (1998)
Paraben allergy
Authors: J. E. Nagel
Journal: JAMA (1977)

A hydrocortisone preparation containing methylparaben and propylparaben provoked bronchospasm and pruritis when given intravenously to an asthmatic patient, whereas another hydrocortisone preparation without paraben preservative did not. Direct and passive transfer (Prausnitz-Küstner) skin tests for immediate hypersensitivity to parabens were positive. Parabens, frequently employed as bacteriostatic agents, are capable of producing immunologically mediated, immediate systemic hypersensitivity reactions. (<i>JAMA</i>237:1594-1595, 1977)
British Medical Journal
Journal: BMJ (1875)

THE BRI7ISRAMEDICAL 7OURNAL.48I noid space between the outer and inner sheaths of the optic nerve, were mentioned and discussed.The conclusion was that Graefe's ex- planation is insufficient, as is that of Schwalbe-Schmidt, and that that of Benedikt is the least assailable, perhaps because the least demon- strable.Dr. H. D. Noyes said that the theory of extension of fluid from the brain was niot substantiated, but most necropsies showed fluid at the ocular but not at the cerebral end of the nerve.As the nerve approaches the eye, its circulation is increased by the accession of vessels, and around its entrance into the ball a vascular ring is formied.The nerve can only find room for expansion in a longitudinal direction.Caution is necessary in deducing cerebral conditions from examination of the ocular end of the optic nerve.Dr. R. H1.Derby thought that the unreliability of the ophthalmoscope in the diagnosis of cerebral hyperzemia or anmemia was conclusively proved.Dr. Knapp remarked that there was a distinction between two forms of choked disc: that from neuritis descendens, with inflammatory action in the nerve or sheath, and distinct elevation of the disc, and that where fluid existed between the layers of the optic sheath.Blood might sometimes ooze from the brain through the intervaginal space into the eye.He believed that, with few exceptions, neuro-retinitis pointed to cerebral disease.Dr. Dalton considered the absence of arterial pulse in the eye as a remarkable fact, and the pulsationi in the veins under abnormal conditions as still more incomprehensible.We might, perhaps, ex- plain the non-pulsation of the arteries, but not that of the veins.
SOME ASPECTS OF VITAMINS AND RADIANT ENERGY
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Warm up
Journal: British Journal of Sports Medicine (2000)

Warm upTo be voted favourite advertisement by readers of the Scottish edition of the Sun is no mean feat (p79).Gavin Hastings, sporting hero, led the Health Education Board of Scotland's walking promotion that gained this honour.Winning the award was relatively unimportant, but what really mattered was that so many people noticed it.Rarely does sports medicine reach the national consciousness.Another innovative approach that triggered public awareness was the subway poster campaign (p144) which had two unusual and imaginative ideas that were positive, encouraging and had flair.This is a new approach for a message that could become tedious.
Highlights
Journal: JAMA Cardiology (2016)

Spatz and coauthors investigated county-level, risk-standardized 1-year mortality rates after myocardial infarction (MI) for Medicare benefi ciaries from 1999 through 2013.Although hospitalization for MI and mortality rates declined among counties at all income levels, low-income counties lagged behind high-income counties by 4.3 years.In an Editorial, Joynt and Maddox point out that improvements in admission rates and mortality are promising but eff orts must continue to address signifi cant, persistent disparities in cardiovascular health and health outcomes.
Concurrent chemoradiotherapy with cetuximab plus twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.
Authors: C. Hsu, C. Lin, J. C. Cheng, C. Yen, J. Lee, H. Wang, K. Yeh, A. Cheng, Y. Lee
Journal: Journal of Clinical Oncology (2010)

4106 Background: We investigated the efficacy and safety of adding cetuximab into twice-weekly paclitaxel/cisplatin-based concurrent chemoradiotherapy (CCRT), followed by surgery, for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods: Patients with operable ESCC (T3N0-1M0 or T1-3N1M0 or M1a) were treated with paclitaxel (35 mg/m2 1 h on days 1 and 4/week), cisplatin (15 mg/m2 1 h on days 2 and 5/week), cetuximab (400 mg/m2 2 h on day -5, then 250 mg/m2 2 h on day 3/week) and radiotherapy (2 Gy on days 1-5/week). When the accumulated radiation dose reached 40 Gy, the feasibility of esophagectomy was evaluated for all patients. In patients for whom esophagectomy was not feasible, CCRT was continued to a radiation dose of 60-66 Gy. Results: Forty-one patients with ESCC were enrolled, and the majority had T3N1M0 or M1a tumors by endoscopic ultrasonographic staging (95%). All patients received CCRT to 40 Gy. Twenty patients underwent surgery, and 9 patients continued definitive CCRT to 60-66 Gy. Of the scheduled doses of paclitaxel, cisplatin, and cetuximab, 77%, 77%, and 98% were given, respectively. The intent-to-treat pathological complete response rate was 26% (8/31) (95% confidence interval: 9%-51%). At the median follow-up of 10.3 months, the projected one-year progression-free and overall survivals were 69% and 66%, respectively. The most common grade 3/4 toxic effects were leukopenia (64%), neutropenia (18%), esophagitis (9%), and infection (9%). Grade 1, 2, and 3 skin rash occurred in 58%, 30%, and 3% of patients, respectively. Grade 1, 2, 3, and 4 hypomagnesemia occurred in 15%, 6%, 0%, and 6% of patients, respectively. Conclusions: Adding cetuximab to twice-weekly paclitaxel/cisplatin-based CCRT prior to esophagectomy is an active and safe treatment for locally advanced ESCC. No significant financial relationships to disclose.
Operative Cholangiography
Authors: John J. Cronan
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism
Journal: Circulation (2005)

In a randomized trial in patients with proximal deep-vein thrombosis, permanent vena cava filters reduced the incidence of pulmonary embolism but increased that of deep-vein thrombosis at 2 years. An 8-year follow-up was performed to assess their very long-term effect.Four hundred patients with proximal deep-vein thrombosis with or without pulmonary embolism were randomized either to receive or not receive a filter in addition to standard anticoagulant treatment for at least 3 months. Data on vital status, venous thromboembolism, and postthrombotic syndrome were obtained once a year for up to 8 years. All documented events were reviewed blindly by an independent committee. Outcome data were available in 396 patients (99%). Symptomatic pulmonary embolism occurred in 9 patients in the filter group (cumulative rate 6.2%) and 24 patients (15.1%) in the no-filter group (P=0.008). Deep-vein thrombosis occurred in 57 patients (35.7%) in the filter group and 41 (27.5%) in the no-filter group (P=0.042). Postthrombotic syndrome was observed in 109 (70.3%) and 107 (69.7%) patients in the filter and no-filter groups, respectively. At 8 years, 201 (50.3%) patients had died (103 and 98 patients in the filter and no-filter groups, respectively).At 8 years, vena cava filters reduced the risk of pulmonary embolism but increased that of deep-vein thrombosis and had no effect on survival. Although their use may be beneficial in patients at high risk of pulmonary embolism, systematic use in the general population with venous thromboembolism is not recommended.
Phase II trial of cisplatin (C), etoposide (E), and radiation (RT) followed by gemcitabine (G) versus G and docetaxel (D) in stage III A/B unresectable non-small cell lung cancer (NSCLC)
Authors: B. Movsas, C. J. Langer, L. H. Wang, R. M. Jotte, F. Xu, C. Huang, M. Monberg, C. K. Obasaju
Journal: Journal of Clinical Oncology (2008)

7597 Background: SWOG 9504 demonstrated highly promising survival rates for D consolidation after E + C and radiation therapy in pts with locally advanced (LA) NSCLC. However, a recent phase III HOG trial suggested no benefit from single-agent D consolidation compared with observation alone (Hanna ASCO 2007 #7512). The current study was developed to assess the feasibility and efficacy of consolidation with either G alone or G + D after the same chemoradiation schedule as SWOG 9504. Methods: The treatment schema included concurrent C 50 mg/m² Day 1, 8 + E 50 mg/m² Day 1–5 for two 28-day cycles + RT 61–62 Gy over 7 weeks after which pts were randomized to consolidation with either G 1000 mg/m² Day 1, 8 (Arm A) or G 1000 mg/m² Day 1, 8 + D 75 mg/m² Day 1 (Arm B) every 21 days for 3 cycles. Eighty-three pts were registered; 64 were randomized to consolidation. Results: See Table. Conclusions: G or G+D following chemoradiation in LA-NSCLC is well tolerated. Preliminary data indicates that consolidation with G+D resulted in prolonged of PFS time with non-overlapping 95% CIs compared with G alone. The doublet, as expected, resulted in more toxicity, particularly myelosuppression and fatigue. Characteristics/Results Induction Arm A Arm B No. of available pts 83 32 32 Median age 59.0 59.5 59.5 Male gender, n 66 27 26 ECOG Performance Status, n – – – PS 0 32 11 13 PS 1 51 21 19 No. of pts assessed for safety, Consolidation – 32 32 Neutropenia, Grade 3/4 – 22%/6% 28%/28% Febrile Neutropenia, Grade 3/4 0%/0% 0%/6% Thrombocytopenia, Grade 3/4 6%/0% 19%/0% Anemia, Grade 3/4 3%/0% 13%/6% Dyspnea, Grade 3/4 – 3%/0% 6%/6% Pneumononitis, Grade 3/4 0%/0% 0%/0% Fatigue, Grade 3/4 6%/0% 16%/0% Alopecia, Grade 2 3% 3% Esophagitis, Grade 3/4 0%/0% 0%/0% No of Cycles of Consolidation – – – One 6% 6% Two 3% 25% Three 91% 69% Response to Chemoradiation – – – No. assessed 83 32 32 CR 0% 6% 9% PR 45% 69% 72% SD 22% 25% 3% PD 4% 0% 0 Unknown 30% 0% 13% RR – 75% 81% (95% CI) – (57, 89) (64, 93) No. events for PFS – 26 10 Median PFS, months 8.3 m 24.3 m (95% CI) (5.4, 9.9) (10.6, NE) Number for survival – 32 32 Mean follow-up for survival, months 24.0 19.6 No. events for survival 15 7 Median survival, months 20.1 m NR (95% CI) (13.0, NR) (21.3, NR) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Eli Lilly and Company Eli Lilly and Company Eli Lilly and Company Eli Lilly and Company
Correction: Update in Pulmonary Medicine
Journal: Annals of Internal Medicine (1999)

Corrections6 July 1999Correction: Update in Pulmonary MedicineFREESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-1-199907060-00032 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the recent Update in Pulmonary Medicine (1), the term “Löffler syndrome” was used incorrectly on page 809. The sentence should read “Up to 15% of cases begin acutely with the Lofgren syndrome: erythema nodosum and bilateral hilar lymphadenopathy.”Reference1. King TE. Update in pulmonary medicine. Ann Intern Med. 1998;129:806-12. LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 6 July 1999Volume 131, Issue 1Page: 74KeywordsErythemaPulmonary medicine ePublished: 15 August 2000 Issue Published: 6 July 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies
Authors: Edward Agura, R. Brian Berryman, Luis Pineiro, Mirjana Tadic-Ovcina, Ryan Woelfel, Estil A. Vance, Joseph W. Fay
Journal: Blood (2008)
The management of ruptured abdominal aortic aneurysms in rural Colorado. With a historical note on Kit Carson's death
Authors: C. M. Abernathy
Journal: JAMA (1986)

Kit Carson died of a ruptured aneurysm in rural Colorado in 1868. Since that time, techniques for management of aortic aneurysms have been developed and disseminated to rural areas with small hospitals. A survey of six Colorado rural hospitals' experience with ruptured abdominal aortic aneurysms is presented. Fifty-seven ruptured aneurysms had been managed during periods ranging from three to ten years. The average time to the operating room was 3.5 to 4.0 hours after hospital arrival and less than 45 minutes after diagnosis. Of those cases arriving with a systolic blood pressure less than 100 mm Hg, the mortality was 56% The overall mortality was 53%. Groups are analyzed according to preoperative delay, occurrence of shock, and other risk factors. The results are compared with several series from metropolitan hospitals. Techniques of management that are of potential benefit in low-volume vascular case settings are discussed. (<i>JAMA</i>1986;256:597-600)
Fat Embolism. Treatment with Lytic Cocktail and Surface Cooling
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene expression profiling of <i>BRCA1</i>-mutant human breast cancer cells after exposure to tamoxifen plus estrogen
Authors: C. D. Murphy, A. B. Olshen, S. Chuai, A. Viale, S.-W. Kim, P. I. Borgen, C. Hudis, J. Boyd
Journal: Journal of Clinical Oncology (2004)

9620 Background: Tamoxifen has been shown to reduce the risk of estrogen receptor (ER)-positive breast cancer in high-risk patients, including BRCA mutation carriers. However, as tumors in BRCA mutation carriers are largely ER-negative, tamoxifen efficacy in this high-risk population remains controversial. Toward that end, we hypothesized that acute tamoxifen exposure may induce similar changes in the gene expression profiles of ER-negative, BRCA1-mutant cells and ER-positive, BRCA1 wild-type cells, which may account for a chemoprotective effect of tamoxifen in both these populations. Methods: ER-positive (MCF7, T-47D, ZR-75–1), ER-negative (MDA-MB-436, SK-BR-3), and BRCA1-mutant, ER-negative (HCC1937) human breast cancer cells were cultured in steroid hormone-free media for 5 days followed by treatment with 10 nM 17-beta estradiol plus 100 nM 5-hydroxytamoxifen or vehicle alone for 8 hours. Total RNA from each cell line was isolated and subjected to gene expression profiling using the Affymetrix U133A Gene Chip oligonucleotide array. Results: The impact of tamoxifen plus estrogen exposure on gene expression was estimated, on a gene by gene basis, by taking the difference between the expression of treated cells and the average expression of the untreated cells. For each gene, confidence intervals (CI) were determined for the mean difference in expression between HCC1937 and ER-positive cells and HCC1937 and ER-negative cells. Genes were identified for which the CI included zero for ER-positive cells and for which the CIs did not overlap. 334 genes were identified which followed this pattern. Over-represented groups of genes included those involved in tumor suppression such as MAPK9 and FAF1 and cell cycle arrest genes including CDKN1B and TSG101. Conclusions: We have identified genes for which the influence of tamoxifen plus estrogen in BRCA1-mutant, ER-negative cells is more similar to its influence in wild-type BRCA1, ER-positive cells than wild-type BRCA1, ER-negative cells. Investigation of these genes may present insight into the molecular mechanism through which tamoxifen may prevent breast cancer in BRCA1 mutation carriers. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca
Lymphoma of pulmonary mucosa-associated lymphoid tissue: CT scan findings and pathological correlations
Authors: M Wislez, J Cadranel, M Antoine, B Milleron, M Bazot, C Mayaud, MF Carette
Journal: European Respiratory Journal (1999)

The aim of this study was to describe the lesions of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma observed by means of computed tomography (CT) and to determine the value of CT in the management of this disease. Sixty six CT scans were performed in 13 consecutive cases of histologically proven pulmonary MALT lymphoma at the time of diagnosis (n=13) or periodically (n=53). They were reviewed separately with chest radiographs by consensus between two observers. Pulmonary abnormalities were described and compared to histopathological findings on surgical specimens from seven patients. At the time of diagnosis, elementary lesions observed by means of CT consisted of nodular areas of attenuation (12 of 13), linear areas of attenuation (eight of 13) and consolidations (six of 13). All these lesions were centred on airways that appeared dilated in seven cases and were more often bilateral and multiple on CT than on the chest radiographs. CT abnormalities correlated with gross pathological appearance and were related to a lymphomatous infiltration with a peribronchovascular distribution. Pathological examination also confirmed the presence of dilated airways within lymphomatous lesions and showed that the bronchial wall was respected. During follow-up, in patients on chemotherapy, response, relapse or progression were easily identified by means of plain radiography. In the initial evaluation, computed tomography contributed to the choice of therapeutic strategy, avoiding unnecessary surgical resection in one-third of patients. By contrast, it is unclear whether computed tomography is useful for post-treatment follow-up of mucosa-associated lymphoid tissue.
The Lympathics. General Anatomy of the Lymphatics, by G. Delamere. Special Study of the Lympathics in Different Parts of the Body, by P. Poirier, Professeur d'Anatomie a la Faculté de Médecine a Paris, Chirurgien des Hôpitaux, and B. Cunéo, Professeur agrégé a la Faculté de Médecine de Paris. Authorized English Edition by Cecil H. Leaf. M.A., M.B. (Cantab.) F.R.C.S. (Eng.), Assistant Surgeon to the Cancer Hospital. With 117 Illustrations and Diagrams.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hair casts
Authors: RODNEY P.R. DAWBER
Journal: British Journal of Dermatology (1979)

The literature on hair casts suggests they are rare even though Kligman intimated in 1957 that in some scalp diseases they might well be common. In this study, casts have been looked for in a group of orthokeratotic and parakeratotic scalp conditions. Hair casts are indeed common in psoriasis, pityriasis amiantacea, pityriasis capitis and seborrhoeic dermatitis. No casts were seen in women with traction hair styles or in those regularly using hair sprays.